We are live on ! Find out more
OCRX

Ocera Therapeutics
OCRX

Delisted

OCRX was delisted on the 8th of December, 2017.

32 hedge funds and large institutions have $22.4M invested in Ocera Therapeutics in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 5

6% less funds holding

Funds holding: 34 → 32 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

73% less capital inflows, than outflows

Capital inflows: $1.18M | Capital outflows: $4.34M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
32
Holders Change
-2
Holders Change %
-5.88%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
14
Reduced
5
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OCRX Hedge Fund Activity: Q2 2015 in Review

32 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics (OCRX) for Q2 2015, worth a combined $22.4M — down 27% from $30.7M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of OCRX and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 14 added.

The largest buyer was Endurant Capital Management, adding an estimated $276K. The largest seller was RA Capital Management, exiting entirely with an estimated $1.97M sold.

  • 32 institutional investors held Ocera Therapeutics (OCRX) as of Q2 2015, down from 34 in Q1 2015.
  • Funds reported $22.4M of Ocera Therapeutics stock for Q2 2015, down 27% quarter-over-quarter.
  • 4 funds opened new Ocera Therapeutics positions in Q2 2015 and 6 closed out, a net change of -2 holders.
  • The largest Ocera Therapeutics buyer in Q2 2015 was Endurant Capital Management, an estimated $276K added.
  • The largest Ocera Therapeutics seller in Q2 2015 was RA Capital Management, an estimated $1.97M sold.

Based on aggregated 13F filings for Q2 2015.